This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Drug Stocks Poised to Stage Comeback

Momenta Pharmaceuticals (MNTA - Get Report)

Cambridge, Mass.-based Momenta is a biotechnology company with a product pipeline of both complex mixture generic and novel drugs. The company's M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox, a low molecular weight heparin used to prevent and treat deep vein thrombosis. Momenta's second major generic product candidate is a generic version of Copaxone, a drug used to reduce the frequency of relapses in patients with Relapse-Remitting Multiple Sclerosis. On the horizon, Momenta's lead novel drug candidate has been engineered to support the treatment of acute coronary syndromes, or ACS.

Shares of the company spiked up to $26 a share last July on news of FDA approval for its generic anti-clotting drug, but retreated back to $15 by the end of the year over valuation worries. Auer says the company's pipeline, earnings growth and partnership with Sandoz will help propel the stock back near last summer's highs.

"Momenta has nearly 200 employees who have figured out a better way to make drugs that attack blood clots. Earnings and revenues rose drastically in 2010 at Momenta, and we are confident this will continue in 2011," says Auer.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player
3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
JNJ $112.75 0.00%
MRK $55.30 0.00%
MNTA $9.76 0.00%
PFE $32.80 0.00%
XLV $70.19 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs